The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Clinical study on Shenmai Injection combined with salmeterol xinafoate and fluticasone propionate in treatment of chronic obstructive pulmonary disease complicating with respiratory failure
Author(s): 
Pages: 440-444
Year: Issue:  4
Journal: World Phytomedicines

Keyword:  Shenmai InjectionSalmeterol Xinafoateand Fluticasone Propionate Powder for inhalationchronic obstructive pulmonary diseaserespiratory failure;
Abstract: Objective To investigate the clinical effect of Shenmai Injection combined with Salmeterol Xinafoateand Fluticasone Propionate Powder for inhalation in treatment of chronic obstructive pulmonary disease(COPD) complicating with respiratory failure. Methods Patients(78 cases) with COPD complicating with respiratory failure in Department of Respiratory, Chongqing Sanbo Changan Hospital from June 2013 to June 2015 were enrolled in this study. According to the different treatment plan, patients were divided into control and treatment groups, and each group had 39 cases. The patients in the control group were aerosol inhalation administered with Salmeterol Xinafoateand Fluticasone Propionate Powder for inhalation on the basis of conventional treatment, 1 suck/time, twice daily. The patients in the treatment group were iv administered with Shenmai Injection on the basis of control group, 100 m L/time, once daily. The patients in two groups were treated for 14 d. After treatment, the efficacy was evaluated, and arterial blood gas indexes, pulmonary function indexes, WBC, CRP, and PCT in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 79.49% and 94.87%, respectively, and there was difference between two groups(P < 0.05). After treatment, p O2 and PH in two groups were significantly increased, but the p CO2 in two groups was significantly decreased, and the differences were statistically significant in the same group(P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant differences between two groups(P < 0.05) After treatment, FEV1, FVC, and FEV1/FVC in two groups were significantly increased, and the differences were statistically significant in the same group(P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant differences between two groups(P < 0.05). After treatment, WBC, CRP, and PCT in two groups were significantly decreased, and the differences were statistically significant in the same group(P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant differences between two groups(P < 0.05). Conclusion Shenmai Injection combined with Salmeterol Xinafoateand Fluticasone Propionate Powder for inhalation has clinical curative effect in treatment of COPD complicating with respiratory failure, and can reduce inflammatory reaction in respiratory tract, significantly improve pulmonary function, which has a certain clinical application value.
Related Articles
No related articles found